Lotus Pharmaceutical Co., Ltd.

TWSE:1795 주식 보고서

시가총액: NT$74.7b

Lotus Pharmaceutical 관리

관리 기준 확인 1/4

Lotus Pharmaceutical CEO는 Petar Vazharov, Jan2018 에 임명되었습니다 의 임기는 6.83 년입니다. 는 NT$ 281.50M 가치에 해당하는 회사 주식의 0.38% 직접 소유합니다. 281.50M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 1.4 년입니다.

주요 정보

Petar Vazharov

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기6.8yrs
CEO 소유권0.4%
경영진 평균 재임 기간3.3yrs
이사회 평균 재임 기간1.4yrs

최근 관리 업데이트

Recent updates

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

CEO 보상 분석

Petar Vazharov 의 보수는 Lotus Pharmaceutical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

NT$4b

Jun 30 2024n/an/a

NT$4b

Mar 31 2024n/an/a

NT$4b

Dec 31 2023n/an/a

NT$4b

Sep 30 2023n/an/a

NT$4b

Jun 30 2023n/an/a

NT$5b

Mar 31 2023n/an/a

NT$4b

Dec 31 2022n/an/a

NT$3b

Sep 30 2022n/an/a

NT$3b

Jun 30 2022n/an/a

NT$1b

Mar 31 2022n/an/a

NT$1b

Dec 31 2021NT$35mNT$28m

NT$1b

Sep 30 2021n/an/a

NT$1b

Jun 30 2021n/an/a

NT$1b

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$18mNT$14m

NT$1b

Sep 30 2020n/an/a

NT$848m

Jun 30 2020n/an/a

NT$769m

Mar 31 2020n/an/a

NT$519m

Dec 31 2019NT$13mNT$7m

NT$663m

보상 대 시장: TW 시장에서 비슷한 규모의 회사에 비해 Petar 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Petar 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Petar Vazharov

6.8yrs

테뉴어

NT$34,721,000

보상

Mr. Petar Antonov Vazharov serves as a Director at Alvogen Korea Co. Ltd. Since March 31, 2021. He is an Executive Vice President of the Asia Pacific Region of Alvogen Group.He is General Manager of Alvog...

리더십 팀

이름위치테뉴어보상소유권
Petar Vazharov
CEO & Director6.8yrsNT$34.72m0.38%
NT$ 281.5m
Eeling Chan
Chief Financial Officer8yrsNT$5.19m0.010%
NT$ 7.5m
Vamsi Kosaraju
Chief Operations Officerno data데이터 없음데이터 없음
Gwen Hsieh
Chief Information Officer3.3yrs데이터 없음0.0084%
NT$ 6.3m
Yu-Ying Yang
Associate Director of Co-Operate Communicationno data데이터 없음데이터 없음
Boon Tan
Deputy General Managerno data데이터 없음0.0077%
NT$ 5.8m
Edin Buljubasic
Vice Presidentno data데이터 없음0.057%
NT$ 42.2m
Yingming Yue
Vice Presidentno data데이터 없음0.011%
NT$ 8.4m
Valerie Lau
Chief Commercial Officer-APACless than a year데이터 없음데이터 없음
Manish Chawla
Vice President of Research and Developmentno data데이터 없음0.026%
NT$ 19.7m

3.3yrs

평균 재임 기간

경험이 풍부한 관리: 1795 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Petar Vazharov
CEO & Director10.2yrsNT$34.72m0.38%
NT$ 281.5m
Vilhelm Wessman
Chairman9.6yrsNT$959.00k데이터 없음
Karl Alexius Tiger Karlsson
Independent Director1.4yrs데이터 없음데이터 없음
Oranee Tangphao-Daniels
Director2.4yrs데이터 없음데이터 없음
Arni Hardarson
Representative Directorless than a yearNT$959.00k데이터 없음
Yves Hermes
Director2.4yrs데이터 없음데이터 없음
Chuan-Fen Wang
Independent Dierctor1.4yrs데이터 없음데이터 없음
Nat Ativitavas
Representative Director1.2yrs데이터 없음데이터 없음
Krisana Winitthumkul
Director2yrs데이터 없음데이터 없음
Ivy Yang
Independent Directorless than a year데이터 없음데이터 없음
Thariswan Tiensawat
Representative Directorless than a year데이터 없음데이터 없음

1.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 1795 의 이사회는 경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.